Biozoom's Advanced Nanospectroscopy Based On Licensable, Cutting-Edge Intellectual Property With Many Possible Applications More than 15 international patents and pending patents comprise a potential revenue source and a powerful R&D resource for licensees
AGOURA HILLS, Calif., June 19, 2013 /PRNewswire/ -- Biozoom (OTC QB: BIZM), developer of the world's first portable, handheld device for real-time spectroscopic analysis of biomarkers in the human body, is willing to discuss intellectual property (IP) licensing and other models of partnership. "We believe in innovation and would like to help foster it in companies that share our values," said Hardy Hoheisel, Biozoom's CEO.
Developing new applications for handheld and nano-scale spectroscopy will remain the company's core business. Licensing Biozoom's intellectual property to other innovative companies would be an additional revenue stream for Biozoom.
The patent-supported technology underlying the Biozoom scanner has been tested in clinical trials at respected institutions in Germany. Biozoom's portfolio of patented and patent-pending advancements span areas as diverse as optics, temperature drift, nanofiltration, data base management, spectroscopy and more.
Biozoom's optical work alone has a myriad of potential applications outside of the company's strategic core health and wellness applications. For example, Biozoom's miniaturization of the Fabry-Perot Filtration could also be widely useful to improve future businesses. Where digital cameras use three filters to capture images, Biozoom's nanofiltration allows 256 filters to capture fine detail in a 1 mm by 1 mm area. Miniaturization allows for this technology to be embedded into systems and products where imaging data might prove useful but is otherwise unavailable. "The potential of this technology is greater than one company can exploit fully," said Biozoom's Chief Technology Officer, Dr. Wolfgang Kocher. "We hope that our intellectual property assets can be licensed to and utilized by other companies for a myriad of commercial uses outside of the health and wellness industries."
Biozoom is an innovative technology development company, specializing in the commercialization of our advances in mobile spectroscopy. Our intellectual property portfolio and ongoing research are positioned to apply Biozoom's technology breakthroughs to a wide range of markets. Our first consumer product, the Biozoom scanner, gives people the feedback they need to manage their health, wellness and fitness on demand. Tested in leading health institutions, our scanner is the first of its kind—a handheld, transdermal device for measuring biomarkers, including antioxidant levels, at the click of a button. Scan results—and customized wellness coaching based on those biomarkers—are sent instantly to a smartphone or online account. The scanner will enable leaders in the health and wellness industry to create new levels of customer loyalty and revenues as a result. For more information, visit www.biozoom.net.
This press release contains "forward-looking statements". Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, and specifically references to future potential purchase orders and re-orders from consumers and distributors. The reader can identify these forward-looking statements by forward-looking words such as "may," "will," "expect," "potential," "anticipate," "forecast," "believe," "estimate," "project," "plan," "continue" or similar words. The reader should read statements that contain these words carefully because they discuss future expectations, contain projections of future results of operations or of financial condition, or state other forward-looking information. Forward-looking statements include, but are not limited to, statements regarding potential products, customers, revenues, expansion efforts, and future plans and objectives of Biozoom, Inc. ("Biozoom"). The risk factors listed in our disclosure documents and the cautionary language therein provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations and projections described by Biozoom in its forward-looking statements. Actual results relating to, among other things, product launch, sales, customer acceptance and market share could differ materially from those currently anticipated in such statements. Factors affecting forward-looking statements include: consumer preferences, competition from more established brands, ability to develop market share; changes in the operating costs; changes in economic conditions, foreign exchange and other financial markets; changes of the interest rates on borrowings; changes in the investments levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Biozoom operates; technological, mechanical and operational difficulties encountered in connection with Biozoom's development activities; and labor relation matters and costs. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Biozoom from time to time with the Securities and Exchange Commission and other regulatory authorities.